Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) endorsed the American Medical Association’s late-2025 policy expanding protections against occupational ionizing radiation. The company highlights its LIBERTY Endovascular Robotic System as a safety solution: ACCESS-PVI showed a 92% relative reduction in radiation exposure. LIBERTY is FDA-cleared, single-use, remotely operated, entered a Limited Market Release in late 2025, and aims for a Full Market Release at SIR in April 2026.

The system also enables seated operation away from radiation, reducing reliance on heavy PPE and musculoskeletal strain for providers.

Positive

• 92% relative radiation reduction in ACCESS-PVI study
• FDA-cleared single-use remotely operated peripheral system
• Limited Market Release commenced in late 2025
• Full Market Release targeted for April 2026 at SIR

Negative

• Commercial availability limited to Limited Market Release since late 2025

Key Figures

Radiation reduction: 92% relative reduction Planned full market release: April 2026

2 metrics

Radiation reduction 92% relative reduction ACCESS-PVI Study using LIBERTY

Planned full market release April 2026 Full Market Release at SIR conference

Market Reality Check

Price: $2.39 Vol: Volume 1,689,577 is at 0....

low vol

$2.39 Last Close

Volume Volume 1,689,577 is at 0.53x the 20-day average, suggesting subdued trading interest pre‑announcement. low

Technical Shares at $2.39 were trading below the $2.58 200-day moving average ahead of this news.

Peers on Argus

Peers in Medical Instruments & Supplies showed mixed moves, with names like AVR ...

1 Up 1 Down

Peers in Medical Instruments & Supplies showed mixed moves, with names like AVR and KRMD up while INFU, STXS and NYXH were down, indicating stock-specific rather than broad sector momentum.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Operations/geopolitics update	Positive	-3.6%	Confirmed stable operations and U.S./Israel activity despite geopolitical events.
Feb 24	Hospital adoption	Positive	+23.9%	Tampa General Hospital became first Florida adopter post‑FDA clearance.
Feb 19	Conference showcase	Positive	+2.4%	CEO featured on innovation summit panel highlighting LIBERTY and full release plans.
Feb 12	Conference visibility	Positive	+4.5%	LIBERTY highlighted at major endovascular therapy conference as single‑use robotic system.
Feb 05	Oncology meeting presence	Positive	-6.9%	Showcased LIBERTY at oncology meeting to support adoption during limited release.

Pattern Detected

Recent LIBERTY commercialization and visibility updates have generally seen positive price reactions, but there are notable selloffs on otherwise positive news, indicating inconsistent follow-through.

Recent Company History

Over the past month, Microbot has repeatedly highlighted commercialization of its LIBERTY Endovascular Robotic System, including conference showcases, early hospital adoption, and operational stability amid geopolitical events. Several of these updates—particularly Tampa General Hospital’s adoption on Feb 24, 2026—were followed by strong positive moves, while others, such as the Mar 3, 2026 stability update, coincided with declines. Today’s focus on alignment with AMA radiation-safety policy fits the ongoing push to position LIBERTY as a differentiated, safety-oriented robotic solution ahead of the planned full market release at SIR in April 2026.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-28

The company has an active S-3/A shelf amendment filed on 2025-10-28, which adds Rule 473(b) language for automatic effectiveness and updates a cross-reference without changing the prospectus. Listed issuance and distribution expenses total $25,000.00, including an SEC registration fee of $404.02. The shelf has recorded 2 recent usage events via Form 424B3 on 2025-11-19.

Market Pulse Summary

This announcement underscores how Microbot is aligning LIBERTY with the AMA’s recently adopted polic...

Analysis

This announcement underscores how Microbot is aligning LIBERTY with the AMA’s recently adopted policy to better protect healthcare professionals from ionizing radiation. The ACCESS‑PVI Study reported a 92% relative reduction in radiation exposure using LIBERTY, supporting its safety-focused positioning. The company remains in limited market release, targeting a full market launch at the SIR conference in April 2026. Observers may watch for additional hospital adoptions, utilization data, and any further regulatory or capital-markets developments.

Key Terms

ionizing radiation, endovascular, peripheral endovascular procedures, fda cleared, +1 more

5 terms

ionizing radiation medical

"efforts to protect health care professionals from ionizing radiation."

High-energy particles or waves (such as X-rays, gamma rays, or certain fast-moving particles) that can remove electrons from atoms and change chemical structures; imagine tiny, invisible billiard balls or flashes that can knock pieces out of place at the atomic level. Investors care because exposure or use of ionizing radiation drives strict safety rules, permits, cleanup costs, product approvals and liability risks for companies in healthcare, energy, manufacturing and environmental services.

endovascular medical

"LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

peripheral endovascular procedures medical

"robotic system for peripheral endovascular procedures, and it is designed for precise"

Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.

fda cleared regulatory

"LIBERTY is the only FDA cleared, single-use, remotely operated robotic system"

FDA cleared means the U.S. Food and Drug Administration reviewed a medical device and agreed it is similar enough to an already allowed product to be marketed in the United States. Think of it like a new car model using largely the same, proven parts as an earlier model — the regulator gives a green light for sales but does not imply the more extensive testing required for full approval. For investors, clearance signals regulatory access to the U.S. market and typically lowers commercialization risk compared with no clearance.

robotic system technical

"LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure"

A robotic system is a combination of machines, sensors and software that carries out physical tasks with various levels of independence — from guided arms on factory floors to medical robots that assist surgeons. For investors, robotic systems matter because they can lower labor costs, boost speed and precision, or enable new products and services; like a smart, tireless worker, they can change a company’s productivity, margins and growth potential.

AI-generated analysis. Not financial advice.

LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers

HINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, commends the American Medical Association’s (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for health care professionals and trainees who may face occupational radiation exposure. The policy emphasizes the importance of continued research into the health effects of cumulative exposure to ionizing radiation, the effectiveness of Personal Protection Equipment (PPE), and education and training to minimize occupational risk to physicians and to their patients.

Microbot believes that this guidance underscores the growing need for solutions that enhance safety in interventional procedures, creating meaningful opportunities for technologies like LIBERTY. The LIBERTY System is remotely operated, enabling physicians and staff to perform procedures away from the radiation source. In the ACCESS-PVI Study, using LIBERTY demonstrated a 92% relative reduction in radiation exposure.

Prolonged exposure to radiation often has long-term effects that can lead to a host of health issues, including cancer, cardiovascular disease, reproductive health effects, and cataracts. This risk has also been cited as contributing to the staffing shortage in the endovascular space, and especially in interventional radiology, which currently ranks number two among specialties with highest physician shortages. It disproportionately affects women, who often cite radiation exposure and the physical demands of wearing lead aprons as barriers to entering or advancing in the field. The LIBERTY System’s wireless operated capabilities allow healthcare providers to position themselves away from the radiation source and operate in a seated position, reducing reliance on heavy PPE, thereby lessening musculoskeletal strain.

“Prolonged exposure to radiation and staffing shortages are rising concerns among healthcare professionals in the endovascular space,” commented Harel Gadot, CEO, President and Chairman. “We believe that these challenges strain an already overburdened health care system, impacting patient care, and widening the skills gap required to address the medical concerns. We also believe that LIBERTY can play a major role in addressing these challenges and supporting better care for both providers and their patients.”

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the Limited Market Release (LMR) of the LIBERTY system in late 2025 and plans for a Full Market Release (FMR) at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

What radiation reduction did Microbot report for LIBERTY (MBOT) in ACCESS-PVI?

A direct answer: LIBERTY demonstrated a 92% relative reduction in radiation exposure in ACCESS-PVI. According to the company, that result highlights the system’s remote operation advantage for clinicians during endovascular procedures.

Is the LIBERTY system FDA cleared and what procedures does MBOT target?

Direct answer: LIBERTY is FDA-cleared for peripheral endovascular procedures. According to the company, the single-use, remotely operated system targets peripheral vascular interventions to reduce radiation and physical strain on staff.

When did Microbot start commercial sales of LIBERTY (MBOT) and what’s next?

Direct answer: The company began a Limited Market Release in late 2025 and plans a Full Market Release at SIR in April 2026. According to the company, the April launch aims to deepen market adoption.

How does LIBERTY reduce physical strain for healthcare providers (MBOT)?

Direct answer: LIBERTY enables remote, seated operation away from the radiation source, reducing heavy PPE use and musculoskeletal strain. According to the company, wireless operation helps address staff ergonomic and retention concerns in endovascular care.

What relevance does the AMA policy have for Microbot Medical (MBOT)?

Direct answer: The AMA’s late-2025 policy broadens protections against occupational ionizing radiation, aligning with LIBERTY’s safety goals. According to the company, this guidance underscores demand for technologies that limit staff radiation exposure.

Will the LIBERTY Full Market Release at SIR impact MBOT’s commercialization timeline?

Direct answer: Microbot plans a Full Market Release at the SIR conference in April 2026 to showcase LIBERTY and accelerate adoption. According to the company, the SIR event is intended to expand clinical visibility and commercial uptake.